CN108851071A - Sea-buckthorn VP alimentation composition and its preparation method and application - Google Patents

Sea-buckthorn VP alimentation composition and its preparation method and application Download PDF

Info

Publication number
CN108851071A
CN108851071A CN201811083609.4A CN201811083609A CN108851071A CN 108851071 A CN108851071 A CN 108851071A CN 201811083609 A CN201811083609 A CN 201811083609A CN 108851071 A CN108851071 A CN 108851071A
Authority
CN
China
Prior art keywords
parts
buckthorn
sea
saponin
powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201811083609.4A
Other languages
Chinese (zh)
Inventor
龚晨
于雪
李婷
吴鹏
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
QINGHAI QINGHUA BOZHONG BIOTECHNOLOGY CO Ltd
Original Assignee
QINGHAI QINGHUA BOZHONG BIOTECHNOLOGY CO Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by QINGHAI QINGHUA BOZHONG BIOTECHNOLOGY CO Ltd filed Critical QINGHAI QINGHUA BOZHONG BIOTECHNOLOGY CO Ltd
Priority to CN201811083609.4A priority Critical patent/CN108851071A/en
Publication of CN108851071A publication Critical patent/CN108851071A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Abstract

The present invention provides a kind of sea-buckthorn VP alimentation compositions and its preparation method and application, are related to nutritional preparation technical field.Sea-buckthorn VP alimentation composition is mainly prepared by the raw material of following parts by weight：5-20 parts of sea-buckthorn VP powder, 5-20 parts of seabuckthorn fruit powder and 5-10 parts of triterpene substance；Wherein, triterpene substance includes at least one of triterpenic acid, triterpenoid saponin or triterpene acid esters, preferably triterpenoid saponin.The present invention is using sea-buckthorn VP powder, seabuckthorn fruit powder and triterpene substance as primary raw material, it is full of nutrition, it influences each other between each component, obtain synergistic effect, adjustable digestive tract environment, prevent alimentary canal rubbish and carcinogen from accumulating in vivo, remove the toxin accumulated in blood vessel and capilary, acceptable directly anti-oxidant and removing free radical, enhance the function of intracellular Antioxidative Defense System, there is good prophylactic-therapeutic effect to diabetes, hypertension, hyperlipidemia and cancer, take safe without toxic side effect for a long time.

Description

Sea-buckthorn VP alimentation composition and its preparation method and application
Technical field
The present invention relates to nutritional preparation technical fields, more particularly, to a kind of sea-buckthorn VP alimentation composition and preparation method thereof And application.
Background technique
As people's living standard generally improves, human health problems are more and more prominent.Currently, overweight crowd's ratio Obvious to rise, diabetes, hypertension, hyperlipidemia and cancer have become the significant challenge of China's public health.People are also increasingly More focus on health care, it is desirable to reach prevention and treatment disease by edible medicine, health care product or food, good health and a long life Purpose.
Nutriment currently on the market is many kinds of, but to the control efficiency of diabetes, hypertension, hyperlipidemia and cancer Ineffective, long-term use causes metabolic disturbance, causes endocrine disorder.
In view of this, the present invention is specifically proposed.
Summary of the invention
An object of the present disclosure is to provide a kind of sea-buckthorn VP alimentation composition, existing in the prior art to sugar to alleviate It is ineffective to urinate disease, hypertension, hyperlipidemia and prevention and control of cancer, long-term use causes metabolic disturbance, causes endocrine disorder Etc. technical problems.
Sea-buckthorn VP alimentation composition provided by the invention, is mainly prepared by the raw material of following parts by weight：Sea-buckthorn VP 5-20 parts of powder, 5-20 parts of seabuckthorn fruit powder and 5-10 parts of triterpene substance；Wherein, triterpene substance includes triterpenic acid, triterpenoid saponin Or at least one of triterpene acid esters, preferably triterpenoid saponin.
Further, it is mainly prepared by the raw material of following parts by weight：8-20 parts of sea-buckthorn VP powder, seabuckthorn fruit powder 8-20 Part and triterpene substance 6-10 parts.
Further, it is mainly prepared by the raw material of following parts by weight：8-18 parts of sea-buckthorn VP powder, seabuckthorn fruit powder 8-18 Part and triterpene substance 6-9 parts.
Further, the triterpenoid saponin includes in monosaccharide triterpenoid saponin, disaccharides triterpenoid saponin or trisaccharide triterpenoid saponin At least one, preferably monosaccharide triterpenoid saponin, further preferably monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin.
Further, the mass ratio of the monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin is (1-3)：(4-7), it is excellent It is selected as (1-2)：(4-6)；
Preferably, the monosaccharide oleanolic acid saponin include glucose oleanolic acid saponin, galactolipin oleanolic acid saponin, At least one of lactose oleanolic acid saponin, xylose oleanolic acid saponin or arabinose oleanolic acid saponin；
Preferably, the monosaccharide ursolic acid saponin includes glucose ursolic acid saponin, galactolipin ursolic acid saponin, lactose bear At least one of tartaric acid saponin(e, xylose ursolic acid saponin or arabinose ursolic acid saponin.
Further, further include in parts by weight：1-5 parts and 1-5 parts of wild jujube powder of chitosan oligosaccharide.
Further, it is mainly prepared by the raw material of following parts by weight：5-15 parts of sea-buckthorn VP powder, seabuckthorn fruit powder 5-15 Part, 1-2 parts of monosaccharide oleanolic acid saponin, 4-6 parts of monosaccharide ursolic acid saponin, 2-4 parts of chitosan oligosaccharide and 2-4 parts of wild jujube powder.
The present invention second is designed to provide a kind of preparation method of sea-buckthorn VP alimentation composition, and the preparation method is simple, Easily grasp, it is economical and practical, it can be produced with large-scale development.
The preparation method of sea-buckthorn VP alimentation composition provided by the invention, includes the following steps：By sea-buckthorn VP powder, fructus hippophae Powder, triterpene substance, optional chitosan oligosaccharide and optional wild jujube powder mix to get sea-buckthorn VP alimentation composition.
Third of the present invention is designed to provide a kind of sea-buckthorn VP alimentation composition in preparing drug, health care product or food Using sea-buckthorn VP alimentation composition can be used for preventing and treating diabetes, hypertension, hyperlipidemia and cancer, and long-term use can Figure is kept, is delayed senescence, immunity of organisms is enhanced.
Further, the drug includes sea-buckthorn VP alimentation composition and pharmaceutically acceptable excipient；
Preferably, the excipient includes at least one of filler, disintegrating agent, adhesive, lubricant or flavoring agent；
Preferably, the dosage form of the drug is any one in tablet, pill, granule or oral solution, further excellent It is selected as tablet.
The present invention has the advantages that compared with the existing technology：
Sea-buckthorn VP alimentation composition provided by the invention is main former with sea-buckthorn VP powder, seabuckthorn fruit powder and triterpene substance Material, it is full of nutrition, it influences each other between each component, obtains synergistic effect, adjustable digestive tract environment prevents alimentary canal rubbish It is accumulated in vivo with carcinogen, removes the toxin accumulated in blood vessel and capilary, acceptable directly anti-oxidant and removing is freely Base enhances the function of intracellular Antioxidative Defense System, has good prevention and treatment to diabetes, hypertension, hyperlipidemia and cancer Effect takes safe without toxic side effect for a long time.
The preparation method of sea-buckthorn VP alimentation composition provided by the invention, the preparation method is simple, easily grasps, economical real Favour can be produced with large-scale development.
Sea-buckthorn VP alimentation composition provided by the invention is applied to prepare in drug, health care product or food, can be used for preventing With treatment diabetes, hypertension, hyperlipidemia and cancer, long-term use is able to maintain figure, delays senescence, and enhances immunity of organism Power.
Specific embodiment
Embodiment of the present invention is described in detail below in conjunction with embodiment, but those skilled in the art will Understand, the following example is merely to illustrate the present invention, and is not construed as limiting the scope of the invention.It is not specified in embodiment specific Condition person carries out according to conventional conditions or manufacturer's recommended conditions.Reagents or instruments used without specified manufacturer is The conventional products that can be obtained by commercially available purchase.
According to the first aspect of the invention, the present invention provides a kind of sea-buckthorn VP alimentation compositions, mainly by weighing as follows The raw material of amount number is prepared：5-20 parts of sea-buckthorn VP powder, 5-20 parts of seabuckthorn fruit powder and 5-10 parts of triterpene substance；Wherein, three Terpene substances include at least one of triterpenic acid, triterpenoid saponin or triterpene acid esters, preferably triterpenoid saponin.
Sea-buckthorn also known as arrow-leaved oleaster, fructus hippophae, Hei Ci or acid thorn, fruit shapes are subsphaeroidal or oval, and distribution is extremely wide, two The temperate zone of hemisphere to the torrid zone is all distributed, and northwest, each provinces and regions in North China and southwest in China are also distributed, and China possesses in the world most Sea buckthorn resources abundant.In addition to containing other than protein, fat and carbohydrate in fructus hippophae, also containing needed by human more Kind vitamin and inorganic salts, wherein vitamin content is abundant, including vitamin B1, vitamin B2, Vitamin B9 (folic acid), dimension life Plain C, vitamin E, vitamin K (phylloquinone), citrin and carotenoid etc., especially with Vitamin C content highest, Ji Huju The hat of all fruits and vegetables may be up to 800-1907mg containing vitamin C in every 100g fructus hippophae, reach as high as 2100mg or more.Sea-buckthorn Fruit powder is that sea buckthorn juice is made using spray drying or freeze-drying method, its main feature is that being easy to save, transporting and use.It is husky The nutritional ingredients such as microelement, vitamin, amino acid and natural tartaric acid abundant are enriched in spine fruit powder.Seabuckthorn fruit powder has good Good hypoglycemic, reducing blood lipid, promote lead discharging and it is anti-oxidant the effects of, it is without any side effects.
Sea-buckthorn VP powder (sea-buckthorn citrin) refers to sea-buckthorn biological flavonoids active material, is catechin, white anthocyanidin, flower The general designation of green element, flavones, flavonols, chalcone, deoxidation chalcone, fragrant glycosides and phenolic acid.The main function of sea-buckthorn VP powder in the present invention It can be that capture superoxide radical and hydroxy radical and the activity for strangling them, adjustable digestive tract environment prevent alimentary canal rubbish Rubbish and carcinogen are accumulated in vivo, are removed the toxin accumulated in blood vessel and capilary, are thoroughly improved the elasticity of blood vessel.
Triterpene substance is a kind of basic parent nucleus terpenoid as composed by 30 carbon atoms, in a free form or with Sugar is combined into glycosides or the form of ester exists.Triterpene substance is pentacyclic triterpene substance, including triterpenic acid, triterpene soap in the present invention At least one of glycosides or triterpene acid esters have extensive bioactivity, have hypoglycemic, reducing blood lipid, anti-fat and anti-artery The functions such as atherosis.But triterpenic acid, because of poorly water-soluble, bioavilability is low to be restricted its clinical application, and triterpene soap The water solubility of glycosides and triterpene acid esters is good, greatly improves bioavilability height, especially best with the effect of triterpenoid saponin.
Wherein, sea-buckthorn VP powder for example can be, but be not limited to 5 parts, 6 parts, 7 parts, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 Part, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts or 20 parts；Seabuckthorn fruit powder for example can be, but be not limited to 5 parts, 6 parts, 7 Part, 8 parts, 9 parts, 10 parts, 11 parts, 12 parts, 13 parts, 14 parts, 15 parts, 16 parts, 17 parts, 18 parts, 19 parts or 20 parts；Triterpene substance Such as can be, but be not limited to 5 parts, 6 parts, 7 parts, 8 parts, 9 parts or 10 parts.
Sea-buckthorn VP alimentation composition provided by the invention is main former with sea-buckthorn VP powder, seabuckthorn fruit powder and triterpene substance Material, it is full of nutrition, it influences each other between each component, obtains synergistic effect, adjustable digestive tract environment prevents alimentary canal rubbish It is accumulated in vivo with carcinogen, removes the toxin accumulated in blood vessel and capilary, acceptable directly anti-oxidant and removing is freely Base enhances the function of intracellular Antioxidative Defense System, has good prevention and treatment to diabetes, hypertension, hyperlipidemia and cancer Effect takes safe without toxic side effect for a long time.
In one preferred embodiment, it is mainly prepared by the raw material of following parts by weight：Sea-buckthorn VP powder 8-20 Part, 8-20 parts of seabuckthorn fruit powder and 6-10 parts of triterpene substance.
In one preferred embodiment, it is mainly prepared by the raw material of following parts by weight：Sea-buckthorn VP powder 8-18 Part, 8-18 parts of seabuckthorn fruit powder and 6-9 parts of triterpene substance.
By further adjusting the proportion between each component, the synergistic effect between each component is given full play to, can be improved The quantity and effect of immunocyte increase the growth of immunocyte and the synthesis of antibody, to improve the disease resistance of body, tie up Organismic internal environment balance is held, immunity of organisms is fundamentally improved.
In one preferred embodiment, the triterpenoid saponin includes monosaccharide triterpenoid saponin, disaccharides triterpenoid saponin or three At least one of sugared triterpenoid saponin, preferably monosaccharide triterpenoid saponin, further preferably monosaccharide oleanolic acid saponin and monosaccharide Ursolic acid saponin.
For triterpenic acid because of poorly water-soluble, bioavilability is low to be restricted its clinical application.When polyhydroxy-sugar and triterpenic acid When the position C-3 of aglycon is connected in the form of ehter bond and forms saponin(e, not only its dissolubility has greatly improved, and it is hypoglycemic, Reducing blood lipid, anti-fat and antiatherosclerosis etc. have the effect of more excellent.Triterpenoid saponin includes monosaccharide triterpene soap At least one of glycosides, disaccharides triterpenoid saponin or trisaccharide triterpenoid saponin.Due to the cholesterol type compound of tumor cell surface Far more than normal cell, triterpenoid saponin can be combined with these molecules, inhibit the growth and differentiation of tumour cell, so that triterpene soap Glycosides will not influence normal cell during killing or inhibiting tumour cell, show higher specificity.Triterpenoid saponin energy Body gastrointestinal tract transhipment effect is effectively facilitated, intestinal obstruction is blocked；Body gastrointestinal tract can be reduced to glucose, cholesterol and lipoprotein Absorption, play the role of hypoglycemic, reducing blood lipid and antiatherosclerosis.Monosaccharide oleanolic acid and list in monosaccharide triterpenoid saponin Effect when compound of sugared ursolic acid saponin is more prominent.
In one preferred embodiment, the mass ratio of the monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin is (1-3)：(4-7), preferably (1-2)：(4-6).
Wherein, the mass ratio of monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin such as can be, but be not limited to 1：4, 1：5,1：6,1：7,2：4,2：5,2：6,2：7,3：4,3：5 or 3：7.
Using the monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin of specific proportion, can act synergistically with other components It performs to most preferably, is inhibiting growth of tumour cell and differentiation, adjusting gastrointestinal tract environment, hypoglycemic, reducing blood lipid and anti-atherogenic Hardening aspect shows higher bioactivity, significant effect.
In one preferred embodiment, the monosaccharide oleanolic acid saponin includes glucose oleanolic acid saponin, half In lactose oleanolic acid saponin, lactose oleanolic acid saponin, xylose oleanolic acid saponin or arabinose oleanolic acid saponin It is at least one.
Monosaccharide oleanolic acid saponin is the position C-3 of glucose, galactolipin, lactose, xylose or arabinose and oleanolic acid It is connected in the form of ehter bond and forms saponin(e.Not only its dissolubility has greatly improved, and in hypoglycemic, reducing blood lipid, anti-obesity Have the effect of with antiatherosclerosis etc. more excellent.Monosaccharide in the present invention is not limited to above-mentioned glucose, gala Sugar, lactose, xylose or arabinose.
In one preferred embodiment, the monosaccharide ursolic acid saponin includes glucose ursolic acid saponin, galactolipin At least one of ursolic acid saponin, lactose ursolic acid saponin, xylose ursolic acid saponin or arabinose ursolic acid saponin.
Monosaccharide ursolic acid saponin be the position C-3 of glucose, galactolipin, lactose, xylose or arabinose and oleanolic acid with Ehter bond form connects and forms saponin(e.Not only its dissolubility has greatly improved, and hypoglycemic, reducing blood lipid, it is anti-fat and Antiatherosclerosis etc. has the effect of more excellent.Monosaccharide in the present invention be not limited to above-mentioned glucose, galactolipin, Lactose, xylose or arabinose.
In one preferred embodiment, further include in parts by weight：1-5 parts and 1-5 parts of wild jujube powder of chitosan oligosaccharide.
Chitosan oligosaccharide is called Chitosan poly oligosaccharide, chitin oligo saccharide, chitosan oligomer, scientific name β-Isosorbide-5-Nitrae-oligosaccharides-gucosamine, the degree of polymerization Between 2-20, there is the unexistent higher solubility of chitosan and be easy by many unique functions such as organism absorptions.Shell The amine-based basic group of oligosaccharides can neutralize the acidic materials that cancer cell releases, and change the relied on microenvironment of cancer cell existence, Restore pH value of human body (i.e. to 7.35-7.45 level) to alkaline direction mobile 0.5, improves the activity of macrophage, increase The quantity of macrophage, therefore can effectively eliminate cancer cell.Meanwhile chitosan oligosaccharide is unique positively charged in nature Dietary fiber, and the sugar chain of cancer cell surfaces is all negatively charged, therefore chitosan oligosaccharide can effectively adsorb cancer cell and keep cancer thin A possibility that born of the same parents cannot be detached from basic stitch easily, substantially reduce cancer metastasis.In addition, chitosan oligosaccharide can eliminate human body oxygen freedom Base activates body cell, delays senescence, and skin surface harmful bacteria is inhibited to breed, and performance of keeping humidity is excellent.Chitosan oligosaccharide promotees in enteron aisle Into growth of probiotics, be proliferated the beneficial bacteriums such as lactic acid bacteria and Bifidobacterium in body largely, inhibit Escherichia coli, Salmonella, The growth of the harmful bacterias such as staphylococcus aureus makes internal Tiny ecosystem reach natural equilibrium, to improve the normal physiological of gastrointestinal tract Function.
It is micro- that wild jujube powder contains glucose, fructose, sucrose, vitamin C, riboflavin, carrotene, 13 kinds of amino acid and 36 kinds Secondary element etc. can be rated as " natural multi-vitamin ball ".In addition, being rich in a large amount of dietary fiber, one side of dietary fiber in dateplum persimmon Face promotes gastrointestinal peristalsis, on the other hand increases the secretion of digestive juice, therefore plays the role of good relax bowel and defecation, dietary fiber Reducing blood lipid, hypoglycemic effect can also be played.Pectin is also rich in dateplum persimmon, pectin has good lipid-lowering effect, and gallbladder is solid Alcohol is one of main component of blood lipid, and pectin has very strong water imbibition and indigestibility, and the gel characteristic having can prevent The contact of cholesterol and digestive ferment, bile acid and intestinal mucosa, while bile acid is fettered, and then drop the absorption of cholesterol significantly It is low.
Wherein, chitosan oligosaccharide for example can be, but be not limited to 1 part, 2 parts, 3 parts, 4 parts or 5 parts；Wild jujube powder for example can be, But it is not limited to 1 part, 2 parts, 3 parts, 4 parts or 5 parts.
In one preferred embodiment, it is mainly prepared by the raw material of following parts by weight：Sea-buckthorn VP powder 5-15 Part, 5-15 parts of seabuckthorn fruit powder, 2-3 parts of monosaccharide oleanolic acid saponin, 4-5 parts of monosaccharide ursolic acid saponin, 2-4 parts of chitosan oligosaccharide and wild jujube 2-4 parts of powder.
Sea-buckthorn VP alimentation composition provided by the invention is with sea-buckthorn VP powder, seabuckthorn fruit powder, monosaccharide oleanolic acid saponin, monosaccharide Ursolic acid saponin, chitosan oligosaccharide and wild jujube powder are primary raw material, are influenced each other between each component, and synergistic effect, bioactivity are obtained The effect of height, absorbability is good, no antigen, hypoglycemic, reducing blood lipid and pre- anti-cancer is significant, and long-term use is able to maintain body Type delays senescence, and enhances immunity of organisms.
According to the second aspect of the invention, the present invention provides a kind of preparation method of sea-buckthorn VP alimentation composition, packets Include following steps：By sea-buckthorn VP powder, seabuckthorn fruit powder, triterpene substance, optional chitosan oligosaccharide and optional wild jujube powder mix to get Sea-buckthorn VP alimentation composition.
The preparation method of sea-buckthorn VP alimentation composition provided by the invention, the preparation method is simple, easily grasps, economical real Favour can be produced with large-scale development.
According to the third aspect of the present invention, the present invention provides a kind of sea-buckthorn VP alimentation compositions to prepare drug, protect Application in strong product or food.
Sea-buckthorn VP alimentation composition provided by the invention is applied to prepare in drug, health care product or food, can be used for preventing With treatment diabetes, hypertension, hyperlipidemia and cancer, long-term use is able to maintain figure, delays senescence, and enhances immunity of organism Power.
In one preferred embodiment, the drug includes sea-buckthorn VP alimentation composition and pharmaceutically acceptable tax Shape agent.
In a preferred embodiment of present embodiment, the excipient include filler, disintegrating agent, adhesive, At least one of lubricant and flavoring agent.
In a preferred embodiment of present embodiment, the dosage form of the drug is tablet, pill, granule or mouth Take any one in liquid, further preferably tablet.
When the dosage form of drug is tablet, excipient selects filler, disintegrating agent, adhesive, lubricant and corrigent.
Wherein, filler includes at least one of starch, anhydrous Icing Sugar, dextrin, lactose or microcrystalline cellulose；Disintegrating agent Including in sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, crosslinked polyvinylpyrrolidone and croscarmellose sodium At least one；Adhesive includes in methylcellulose, PVP K30, polyvinylpyrrolidone K15 or starch slurry At least one；Lubricant includes at least one of magnesium stearate, superfine silica gel powder or talcum powder；Corrigent include citric acid, Aspartame, stevioside or medicinal essence (chicken gizzard taste essence or beef flavor).
The preparation method of tablet, includes the following steps：
(a) sea-buckthorn VP alimentation composition is mixed with filler, obtains mixture；
(b) mixture that the step (a) obtains is mixed with disintegrating agent, adhesive and corrigent, pelletizes, obtains Grain；
(c) particle and mix lubricant obtained the step (b), tabletting obtain tablet.
It is crushed after step (a) mixing, crosses 60-100 mesh, preferably 80-100 mesh；The step (b) is using wet Method is pelletized, and through drying after the wet granulation, whole grain obtains particle；The drying temperature is 55-60 DEG C, and the drying time is 0.5-1h。
In order to facilitate the clearer understanding present invention, below in conjunction with embodiment and comparative example to technical side of the invention Case is described further.
Embodiment one
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 5 parts of sea-buckthorn VP powder, 20 parts of seabuckthorn fruit powder, 1 part of single glucose oleanolic acid saponin and single 4 parts of ursolic acid saponin of lactose.
Embodiment two
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 20 parts of sea-buckthorn VP powder, 5 parts of seabuckthorn fruit powder, 3 parts of single glucose oleanolic acid saponin and single 3 parts of ursolic acid saponin of lactose.
Embodiment three
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 8 parts of sea-buckthorn VP powder, 20 parts of seabuckthorn fruit powder, 1 part of single glucose oleanolic acid saponin and single 5 parts of ursolic acid saponin of lactose.
Example IV
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 18 parts of sea-buckthorn VP powder, 8 parts of seabuckthorn fruit powder, 2 parts of single glucose oleanolic acid saponin and single 7 parts of ursolic acid saponin of lactose.
Embodiment five
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder, 2 parts of single glucose oleanolic acid saponin and single 5 parts of ursolic acid saponin of lactose.
Embodiment six
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder, 5 parts of single glucose oleanolic acid saponin and single 2 parts of ursolic acid saponin of lactose.
Embodiment seven
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder, 2 parts of oleanolic acid and single 5 parts of ursolic acid saponin of lactose.
Embodiment eight
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder, single 2 parts and 5 parts of black bearberry acetoacetic ester of oleanolic acid saponin of glucose.
Embodiment nine
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder and single 2 parts of oleanolic acid saponin of glucose.
Embodiment ten
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder and single 5 parts of ursolic acid saponin of lactose.
Embodiment 11
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 10 parts of sea-buckthorn VP powder, 10 parts of seabuckthorn fruit powder, single 2 parts of glucose oleanolic acid saponin, single 5 parts of lactose ursolic acid saponin, chitosan oligosaccharide 3 Part and 3 parts of wild jujube powder.
Embodiment 12
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 5 parts of sea-buckthorn VP powder, 15 parts of seabuckthorn fruit powder, single 1 part of glucose oleanolic acid saponin, single 6 parts of lactose ursolic acid saponin, chitosan oligosaccharide 5 Part and 1 part of wild jujube powder.
Embodiment 13
A kind of sea-buckthorn VP alimentation composition is present embodiments provided, is mainly prepared by the raw material of following parts by weight： 15 parts of sea-buckthorn VP powder, 1 part of seabuckthorn fruit powder, single 2 parts of glucose oleanolic acid saponin, single 5 parts of lactose ursolic acid saponin, chitosan oligosaccharide 1 Part and 5 parts of wild jujube powder.
The preparation method of sea-buckthorn VP alimentation composition, includes the following steps provided by embodiment one to 13：By sea-buckthorn VP powder, seabuckthorn fruit powder, triterpene substance, optional chitosan oligosaccharide and optional wild jujube powder mix to get sea-buckthorn VP alimentation composition.
It should be noted that triterpene substance in each embodiment feeds according to the component in formula, wherein embodiment one Chitosan oligosaccharide and wild jujube powder are free of to 11, omits corresponding addition step.
Embodiment 14 to 28
Sea-buckthorn VP alimentation composition provided by embodiment one to 13 is mixed with excipient, sea-buckthorn VP piece is made.Its In, excipient select 50 parts of filler (maltodextrin), 5 parts of disintegrating agent (sodium carboxymethyl starch), 5 parts of adhesive (starch slurry), 5 parts of lubricant (magnesium stearate) and 2 parts of corrigent (stevioside).
The preparation method of sea-buckthorn VP piece, includes the following steps provided by embodiment 14 to 28：
(a) sea-buckthorn VP alimentation composition is mixed with filler, is crushed, crossed 80 meshes, obtain mixture；
(b) mixture that the step (a) obtains is mixed with disintegrating agent, adhesive and corrigent, wet granulation, 58 DEG C Dry 0.8h, whole grain obtain particle；
(c) particle and mix lubricant obtained the step (b), tabletting obtain sea-buckthorn VP piece.
Comparative example one
This comparative example provides a kind of sea-buckthorn VP alimentation composition, and unlike embodiment five, the content of each component is not In protection scope of the present invention etc.
This comparative example provides a kind of sea-buckthorn VP alimentation composition, is mainly prepared by the raw material of following parts by weight： 1 part of sea-buckthorn VP powder, 30 parts of seabuckthorn fruit powder, 6 parts of single glucose oleanolic acid saponin and single 15 parts of ursolic acid saponin of lactose.
Comparative example two
This comparative example provides a kind of sea-buckthorn VP alimentation composition, and unlike embodiment five, the content of each component is not In protection scope of the present invention etc.
This comparative example provides a kind of sea-buckthorn VP alimentation composition, is mainly prepared by the raw material of following parts by weight： 30 parts of sea-buckthorn VP powder, 1 part of seabuckthorn fruit powder, 4 parts of single glucose oleanolic acid saponin and single 10 parts of ursolic acid saponin of lactose.
Comparative example three
This comparative example provides a kind of sea-buckthorn VP alimentation composition, unlike embodiment five, is free of sea-buckthorn VP powder.
Comparative example four
This comparative example provides a kind of sea-buckthorn VP alimentation composition, unlike embodiment five, is free of seabuckthorn fruit powder.
Comparative example five
This comparative example provides a kind of sea-buckthorn VP alimentation composition, neat without single glucose unlike embodiment five Pier tartaric acid saponin(e and single lactose ursolic acid saponin.
Sea-buckthorn provided by the preparation method Yu embodiment five of sea-buckthorn VP alimentation composition provided by comparative example one to five The preparation method of VP alimentation composition is identical.
Comparative example six to ten
Sea-buckthorn VP alimentation composition provided by comparative example one to five is mixed with excipient, sea-buckthorn VP piece is made.Wherein, Excipient selects 50 parts of filler (maltodextrin), 5 parts of disintegrating agent (sodium carboxymethyl starch), 5 parts of adhesive (starch slurry), lubrication 5 parts of agent (magnesium stearate) and 2 parts of corrigent (stevioside).
The system for the sea-buckthorn VP piece that the preparation method Yu embodiment 19 of sea-buckthorn VP piece provided by comparative example six to ten provide Preparation Method is identical.
The toxicological test of one sea-buckthorn VP alimentation composition of test example
Mouse is taken to be randomly divided into 20 groups, every group 10, half male and half female, respectively blank group, embodiment group (are respectively implemented One to 14 group of example) and comparative example group (respectively one to five group of comparative example).Embodiment group presses 38gkg-1Daily dosage fill The sea-buckthorn VP alimentation composition suspension of stomach embodiment one to 14, comparative example group press 38gkg-1Daily dosage distinguish stomach-filling The sea-buckthorn VP alimentation composition suspension of comparative example one to five, the capacity distilled water such as blank group stomach-filling even fill 14 days, during administration The free diet of animal.
The appearance sign of daily observation administration front and back animal, the variation of behavioral activity hair, stool and urine shape and color, eye, Whether there is or not abnormal secretions etc. for ear, mouth, nose, anus.0,1,3,7,11 and 14 day weighing the weight of animals is being administered respectively, is calculating and increases Rate.After successive administration 14 days, mouse plucks eyeball and takes blood, separates serum, detects glutamic-pyruvic transaminase (ALT), glutamic-oxalacetic transaminease (AST), urea nitrogen (BUN) and inosine (CREA) index.Animal is put to death after taking blood, to the heart, liver and spleen, lung, kidney, brain, sexual gland, first shape Gland, thymus gland and ileum etc. are visually observed, and are weighed and are calculated organ coefficient.Liver, nephridial tissue are taken, with 10% neutral formalin solution It is fixed, it is dyed through graded ethanol dehydration, the transparent paraffin embedding of dimethylbenzene, slice (4-5 μm thick) and HE, optical microphotograph is under the microscope Histopathologic change.
Test result：
(1) appearance sign observes each group without dead example, general signs no abnormality seen.
(2) compared with blank control group group, the heart, liver and spleen, lung, kidney, brain, sexual gland, the first shape of control group and test group mouse The Organ weights such as gland, thymus gland and ileum and organ coefficient difference is not significant.
(3) liver/kidney side effect evaluation, the results are shown in Table 1, table 2.
1 liver side effect evaluation result of table
2 renal adverse effects evaluation result of table
Grouping BUN(mmol·L-1) CREA(μmol·L-1) Overall merit
Embodiment one 6.64±1.10 54.11±6.16 Normally
Embodiment two 6.48±0.98 53.14±5.82 Normally
Embodiment three 6.70±1.14 54.61±4.45 Normally
Example IV 6.80±1.05 55.60±6.01 Normally
Embodiment five 6.76±1.02 54.58±5.62 Normally
Embodiment six 7.10±1.14 54.56±5.73 Normally
Embodiment seven 6.94±1.50 54.14±5.16 Normally
Embodiment eight 6.87±0.98 54.45±6.82 Normally
Embodiment nine 6.90±1.24 55.71±4.45 Normally
Embodiment ten 6.67±1.35 53.66±6.01 Normally
Embodiment 11 6.79±1.12 54.45±5.62 Normally
Embodiment 12 6.84±1.20 54.06±5.16 Normally
Embodiment 13 6.88±0.98 55.14±4.82 Normally
Embodiment 14 6.86±1.31 55.10±3.45 Normally
Comparative example one 6.77±1.25 53.66±6.01 Normally
Comparative example two 6.92±1.12 54.68±5.62 Normally
Comparative example three 6.65±1.30 54.36±6.16 Normally
Comparative example four 6.80±0.98 55.34±5.82 Normally
Comparative example five 6.76±1.14 55.46±5.45 Normally
Blank control group 6.86±1.15 54.66±8.01 Normally
As seen from the above table, compared with blank control group, ALT, AST, BUN and CREA index of each administration group, difference is unknown Aobvious, successive administration 14 days under higher dosage, embodiment group Mouse Liver/renal function is not damaged, and liver/kidney side effect is chosen as " just Often ".
The pharmacodynamic test of two sea-buckthorn VP alimentation composition of test example
(1) lipid of mice is influenced to test
Experimental animal：Kunming mice 300,20 ± 2g of weight, female is fifty-fifty, is ground by Chinese Academy of Medical Sciences's medicinal plant The offer of institute's animal center is provided.
Test method：Mouse dieting high fat diet is given, the formula of high fat diet is network albumen 1kg, L-cysteine 15g, maltodextrin 0.75kg, sucrose 0.35kg, cellulose 0.25kg, soybean oil 0.15kg and lard 1.25kg.Raising 10 weeks Afterwards, the mouse that weight is less than 50g is eliminated, 210 mouse are then chosen, is randomly divided into 21 groups, every group 10, female is fifty-fifty, point It Wei not blank group, positive controls, embodiment group (respectively one to 14 group of embodiment) and comparative example group (respectively comparative example One to five group).Once a day through gastric infusion, dosage is respectively：Each embodiment and comparative example gives 1.5mg/kg/d examination respectively Sample is tested, positive controls give 1.5mg/kg/d rosuvastain calcium, and blank control group gives 0.9% physiology of 0.5mL/10g Salt water continues 8 weeks.Serum total cholesterol TC, low density lipoprotein cholesterol LDL-C, high density lipoprotein level are detected after administration White cholesterol HDL-C and triglycerides TG, the results are shown in Table 3.
Lipid content index in 3 mouse blood of table
As seen from the above table, TC, LDL-C, HDL-C and TG in the embodiment of the present invention one to 14 are compared with blank control group There is significant difference, no significant difference compared with positive controls illustrates provided by the embodiment of the present invention one to 14 Sea-buckthorn VP alimentation composition has good synergistic effect for reducing blood lipid.
(2) mouse blood sugar is influenced to test
Experimental animal：Kunming mice 300,20 ± 2g of weight, female is fifty-fifty, is ground by Chinese Academy of Medical Sciences's medicinal plant The offer of institute's animal center is provided.
Test method：22 DEG C of the temperature and adaptive feeding 7 days under conditions of relative humidity 60% in animal house.It will adapt to Property feed 7 days small white mouse fasting 15h after, streptozotocin 130mg/kg dosage is injected intraperitoneally, surveys fasting blood-glucose after 3 days (BG), BG > 12.0mmol/L person is diabetic mice.210 mouse are chosen, small white mouse is randomly divided into 21 groups, every group 10 Only, female is fifty-fifty, respectively blank group, positive controls, embodiment group (respectively one to 14 group of embodiment) and comparative example Group (respectively one to five group of comparative example).Once a day through gastric infusion, dosage is respectively：Each embodiment and comparative example is given respectively 500mg/kg/d test specimen is given, positive controls give 500mg/kg/d melbine, and blank control group gives 0.5mL/10g 0.9% physiological saline continues 10 days.Tail point is taken a blood sample after administration, is measured mouse fasting plasma glucose concentration with blood glucose meter, is as a result seen Table 4.
4 mouse fasting plasma glucose concentration index of table
As seen from the above table, the fasting plasma glucose concentration in the embodiment of the present invention one to 14 has significantly compared with blank control group Sex differernce, no significant difference compared with positive controls illustrate sea-buckthorn VP provided by the embodiment of the present invention one to 14 Alimentation composition has good synergistic effect for hypoglycemic.
(3) growth of tumour cell is influenced to test
Test material：Murine hepatocarcinoma cell strain S180, provided by case history teaching and research room of the Chinese Academy of Medical Sciences.
Experimental animal：Kunming mice 300,20 ± 2g of weight, female fifty-fifty, Chinese Academy of Medical Sciences's medicinal plants study Institute's animal center provides.
Test method：
Mouse S180The preparation of carcinoma cell strain：The S that will be frozen in liquid nitrogen180Carcinoma cell strain is taken out, and 37 DEG C of warm water are multiple Soviet Union, centrifugal treating abandon frozen stock solution, then plus physiology salt washing twice, it is intraperitoneal to be inoculated in kunming mice, takes under aseptic condition after 7 days Tumor liquid in abdominal cavity, with 1：3 ratios sterile saline dilutes spare.
Mouse S180The inoculation of carcinoma cell strain：Previously prepared tumor liquid is aseptically extracted, under every mouse right axillary It is injected separately into 0.2mL, 210 mouse are chosen after 24 hours, small white mouse is randomly divided into 21 groups, every group 10, female is fifty-fifty, point It Wei not blank group, positive controls, embodiment group (respectively one to 14 group of embodiment) and comparative example group (respectively comparative example One to five group).Once a day through gastric infusion, dosage is respectively：Each embodiment and comparative example gives 8g/kg/d test sample respectively Product, positive controls give 20mg/kg/d cyclophosphamide, and blank control group gives 0.9% physiological saline of 0.5mL/10g, continue 7 days.It weighs after administration, puts to death mouse, remove tumor mass, tumor weight of weighing calculates inhibiting rate, is repeated 3 times, the results are shown in Table 5。
5 mouse tumor cell inhibiting effect of table
Grouping Tumor weight (g) Inhibiting rate (%)
Embodiment one 0.7318±0.1261 49.7
Embodiment two 0.7439±0.1360 48.9
Embodiment three 0.7544±0.1262 48.2
Example IV 0.7438±0.1325 48.9
Embodiment five 0.7554±0.1261 48.1
Embodiment six 0.7633±0.1259 47.6
Embodiment seven 0.7645±0.1345 47.5
Embodiment eight 0.7636±0.1355 47.6
Embodiment nine 0.7628±0.1237 47.6
Embodiment ten 0.7619±0.1236 47.7
Embodiment 11 0.7309±0.1217 49.8
Embodiment 12 0.7308±0.1675 49.8
Embodiment 13 0.7311±0.1315 49.8
Embodiment 14 0.7216±0.1210 50.4
Comparative example one 1.2933±0.1275 11.2
Comparative example two 1.3562±0.1208 6.9
Comparative example three 1.2576±0.1235 13.6
Comparative example four 1.2867±0.1245 11.6
Comparative example five 1.3614±0.1268 6.5
Positive controls 0.7369±0.1215 63.1
Blank control group 1.4563±0.1135 -
As seen from the above table, the tumor weight in the embodiment of the present invention one to 14 is decreased obviously compared with blank control group, Illustrate sea-buckthorn VP alimentation composition provided by the embodiment of the present invention one to 14 for preventing and treating entity tumor with good Good synergistic effect.
(4) Immune Function is tested
Experimental animal：Kunming mice 400,20 ± 2g of weight, female is fifty-fifty, is ground by Chinese Academy of Medical Sciences's medicinal plant The offer of institute's animal center is provided.
Test method：Mouse is randomly divided into two big groups, every group 200, wherein one group of mouse inoculation mouse S180Lotus knurl is thin Born of the same parents' strain (specific method refer to 3), another group is not done inoculated tumour processing, by each big group again with being divided into 20 groups, every group 10, Female is fifty-fifty, respectively blank group, embodiment group (respectively one to 14 group of embodiment) and comparative example group (respectively comparative example One to five group).Once a day through gastric infusion, dosage is respectively：Each embodiment and comparative example gives 8g/kg/d test sample respectively Product, blank control group give 0.9% physiological saline of 0.5mL/10g, continue 7 days, in 30min after the last administration, mouse is quiet through tail Arteries and veins injects india ink 0.05mL/10g, and 2min (t1) and 10min (t2) uses suction pipe from mouse orbit vein after injection 20 μ L of blood is taken, is dissolved in 0.1% sodium carbonate liquor of 2mL and shaking up, sets 751 spectrophotometers colorimetric at wavelength 680nm, is measured Optical density (OD), by cleaning up index K=(lgOD1-lgOD2)/(t1-t2) calculate K value, OD1For the OD value of t1 time, OD2For t1 The OD value of time.Tumor-free mice immune function the results are shown in Table 6, and inoculated tumour immune function of mice the results are shown in Table 7.
6 tumor-free mice Immune Function of table
Grouping Clean up index
Embodiment one 0.0768±0.0126
Embodiment two 0.0759±0.0136
Embodiment three 0.0744±0.0162
Example IV 0.0748±0.0125
Embodiment five 0.0755±0.0126
Embodiment six 0.0733±0.0125
Embodiment seven 0.0735±0.0140
Embodiment eight 0.0736±0.0155
Embodiment nine 0.0748±0.0133
Embodiment ten 0.0749±0.0123
Embodiment 11 0.0769±0.0117
Embodiment 12 0.0768±0.0175
Embodiment 13 0.0771±0.0135
Embodiment 14 0.0776±0.0121
Comparative example one 0.0494±0.0125
Comparative example two 0.0562±0.0128
Comparative example three 0.0576±0.0135
Comparative example four 0.0486±0.0124
Comparative example five 0.03614±0.0126
Blank control group 0.00531±0.0015
7 inoculated tumour immune function of mice of table influences
Grouping Clean up index
Embodiment one 0.0759±0.0133
Embodiment two 0.0749±0.0131
Embodiment three 0.0754±0.0142
Example IV 0.0748±0.0127
Embodiment five 0.0747±0.0131
Embodiment six 0.0740±0.0135
Embodiment seven 0.0735±0.0141
Embodiment eight 0.0746±0.0135
Embodiment nine 0.0738±0.0143
Embodiment ten 0.0746±0.0143
Embodiment 11 0.0783±0.0137
Embodiment 12 0.0768±0.0155
Embodiment 13 0.0776±0.0145
Embodiment 14 0.0756±0.0145
Comparative example one 0.0534±0.0165
Comparative example two 0.0542±0.0138
Comparative example three 0.0546±0.0137
Comparative example four 0.05167±0.0121
Comparative example five 0.03614±0.0120
Blank control group 0.03537±0.0015
As seen from the above table, the K value in the embodiment of the present invention one to 14 is significantly raised compared with blank control group, illustrates this Sea-buckthorn VP alimentation composition provided by inventive embodiments one to 14 can improve the immune function of normal mouse, to inoculated tumour The immune function of mouse has certain facilitation.
Finally it should be noted that：The above embodiments are only used to illustrate the technical solution of the present invention., rather than its limitations；To the greatest extent Present invention has been described in detail with reference to the aforementioned embodiments for pipe, those skilled in the art should understand that：Its according to So be possible to modify the technical solutions described in the foregoing embodiments, or to some or all of the technical features into Row equivalent replacement；And these are modified or replaceed, various embodiments of the present invention technology that it does not separate the essence of the corresponding technical solution The range of scheme.

Claims (10)

1. a kind of sea-buckthorn VP alimentation composition, which is characterized in that be mainly prepared by the raw material of following parts by weight：Sea-buckthorn VP 5-20 parts of powder, 5-20 parts of seabuckthorn fruit powder and 5-10 parts of triterpene substance；Wherein, triterpene substance includes triterpenic acid, triterpenoid saponin Or at least one of triterpene acid esters, preferably triterpenoid saponin.
2. sea-buckthorn VP alimentation composition according to claim 1, which is characterized in that mainly by the raw material of following parts by weight It is prepared：8-20 parts of sea-buckthorn VP powder, 8-20 parts of seabuckthorn fruit powder and 6-10 parts of triterpene substance.
3. sea-buckthorn VP alimentation composition according to claim 1, which is characterized in that mainly by the raw material of following parts by weight It is prepared：8-18 parts of sea-buckthorn VP powder, 8-18 parts of seabuckthorn fruit powder and 6-9 parts of triterpene substance.
4. sea-buckthorn VP alimentation composition according to claim 1-3, which is characterized in that the triterpenoid saponin includes At least one of monosaccharide triterpenoid saponin, disaccharides triterpenoid saponin or trisaccharide triterpenoid saponin, preferably monosaccharide triterpenoid saponin, further Preferably monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin；
Preferably, the mass ratio of the monosaccharide oleanolic acid saponin and monosaccharide ursolic acid saponin is (1-3)：(4-7), it is further excellent It is selected as (1-2)：(5-7) is still more preferably 2：5.
5. sea-buckthorn VP alimentation composition according to claim 4, which is characterized in that the monosaccharide oleanolic acid saponin includes Glucose oleanolic acid saponin, galactolipin oleanolic acid saponin, lactose oleanolic acid saponin, xylose oleanolic acid saponin or I At least one of sugared oleanolic acid saponin of uncle；
And/or the monosaccharide ursolic acid saponin includes glucose ursolic acid saponin, galactolipin ursolic acid saponin, lactose ursolic acid At least one of saponin(e, xylose ursolic acid saponin or arabinose ursolic acid saponin.
6. sea-buckthorn VP alimentation composition according to claim 5, which is characterized in that further include in parts by weight：Shell 1-5 parts and 1-5 parts of wild jujube powder of oligosaccharides.
7. sea-buckthorn VP alimentation composition according to claim 6, which is characterized in that mainly by the raw material of following parts by weight It is prepared：5-15 parts of sea-buckthorn VP powder, 5-15 parts of seabuckthorn fruit powder, 1-2 parts of monosaccharide oleanolic acid saponin, monosaccharide ursolic acid saponin 5- 6 parts, 3-5 parts of chitosan oligosaccharide and 3-5 parts of wild jujube powder.
8. a kind of method for preparing the described in any item sea-buckthorn VP alimentation compositions of claim 1-7, which is characterized in that including such as Lower step：Sea-buckthorn VP powder, seabuckthorn fruit powder, triterpene substance, optional chitosan oligosaccharide and optional wild jujube powder are mixed to get sea-buckthorn VP alimentation composition.
9. a kind of described in any item sea-buckthorn VP alimentation compositions of claim 1-7 or preparation method system according to any one of claims 8 Standby obtained sea-buckthorn VP alimentation composition is preparing the application in drug, health care product or food.
10. application according to claim 9, which is characterized in that the drug includes sea-buckthorn VP alimentation composition and pharmacy Upper acceptable excipient；
Preferably, the excipient includes at least one of filler, disintegrating agent, adhesive, lubricant or flavoring agent；
Preferably, the dosage form of the drug is any one in tablet, pill, granule or oral solution, further preferably Tablet.
CN201811083609.4A 2018-09-17 2018-09-17 Sea-buckthorn VP alimentation composition and its preparation method and application Pending CN108851071A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201811083609.4A CN108851071A (en) 2018-09-17 2018-09-17 Sea-buckthorn VP alimentation composition and its preparation method and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201811083609.4A CN108851071A (en) 2018-09-17 2018-09-17 Sea-buckthorn VP alimentation composition and its preparation method and application

Publications (1)

Publication Number Publication Date
CN108851071A true CN108851071A (en) 2018-11-23

Family

ID=64324358

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201811083609.4A Pending CN108851071A (en) 2018-09-17 2018-09-17 Sea-buckthorn VP alimentation composition and its preparation method and application

Country Status (1)

Country Link
CN (1) CN108851071A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110368391A (en) * 2019-06-21 2019-10-25 中国科学院西北高原生物研究所 Triterpenoid is preparing the purposes in hypoglycemic Related product

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1813827A (en) * 2005-02-04 2006-08-09 向云成 Sea-buckthorn chewing tablet and its preparation
CN101224215A (en) * 2007-01-16 2008-07-23 成都地奥九泓制药厂 Uses of ursolic acid saponin and oleanolic acid saponin in preparing medicine for increasing white blood cell and/or blood platelet
CN102150849A (en) * 2011-01-07 2011-08-17 中国科学院西北高原生物研究所 Seabuckthorn and Nitraria sibirica Pall fruit powder buccal tablet and preparation method thereof
CN102961418A (en) * 2012-11-02 2013-03-13 山西大同大学 Compound Hippophae rhamnoides dipyridamole tablet and preparation method thereof
CN103417588A (en) * 2013-08-23 2013-12-04 中国科学院新疆理化技术研究所 Preparation method of effective part of Hippophae rhamnoides

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1813827A (en) * 2005-02-04 2006-08-09 向云成 Sea-buckthorn chewing tablet and its preparation
CN101224215A (en) * 2007-01-16 2008-07-23 成都地奥九泓制药厂 Uses of ursolic acid saponin and oleanolic acid saponin in preparing medicine for increasing white blood cell and/or blood platelet
CN102150849A (en) * 2011-01-07 2011-08-17 中国科学院西北高原生物研究所 Seabuckthorn and Nitraria sibirica Pall fruit powder buccal tablet and preparation method thereof
CN102961418A (en) * 2012-11-02 2013-03-13 山西大同大学 Compound Hippophae rhamnoides dipyridamole tablet and preparation method thereof
CN103417588A (en) * 2013-08-23 2013-12-04 中国科学院新疆理化技术研究所 Preparation method of effective part of Hippophae rhamnoides

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110368391A (en) * 2019-06-21 2019-10-25 中国科学院西北高原生物研究所 Triterpenoid is preparing the purposes in hypoglycemic Related product
CN110368391B (en) * 2019-06-21 2022-11-08 中国科学院西北高原生物研究所 Application of triterpene compound in preparation of products related to blood sugar reduction

Similar Documents

Publication Publication Date Title
ES2682940T3 (en) Composition comprising ocra for use in reducing the absorption of food fat
CN107105742B (en) Composition for preventing or improving non-alcoholic fatty liver disease comprising white lablab seed extract as active ingredient
GB2529962A (en) Multi-functional composition and preparation method and application thereof
CN102114112A (en) Effervescent tablet for improving immunity and preparation method thereof
CN101856387A (en) Chinese herbal immunopotentiator for chicken
TW201206460A (en) Anti-viral properties of Aloe vera and Acquired Immune Deficiency Syndrome (AIDS) treatment
KR101614574B1 (en) Composition of Diabetes-Improving Effective Constituents by Fermentation Products of the Trifoliate Orange
CN101564160B (en) Food for preventing and treating hyperlipemia and hyperglycemia and preparation method thereof
CN109007224A (en) A kind of pressed candy and preparation method thereof containing Astaxanthin In Haematococcus Pluvialis conditioning female organism
KR101829637B1 (en) A composition for improving, preventing and treating digestion dysfunction, leukocyte reduce, bone marrow suppression by side effects after anti-cancer therapy comprising Rhus verniciflua stoke extract
CN102526339B (en) Formulation of healthcare medicine for regulating blood lipid and enhancing immunity
CN107981351B (en) Dietary microcapsule particle for regulating body fat rate and preparation method thereof
CN102090637A (en) Collagen-containing compound nutritious powder
CN108851071A (en) Sea-buckthorn VP alimentation composition and its preparation method and application
CN103920140B (en) A kind of people is with blood sugar lowering Weight-reducing and lipid-lowering compound preparation
Mao et al. A human milk oligosaccharide, 2′-fucosyllactose, enhances the immunity in mice fed an infant formula milk diet
CN110237117A (en) A kind of soft capsule and preparation method thereof of Menopause anti-aging
JPWO2016136624A1 (en) Immunomodulators and uses thereof
CN105050427B (en) Edible composition and food comprising it, the preparation method of the food
CN111387394A (en) Sea-buckthorn solid beverage for enhancing immunity and inhibiting tumors and preparation method thereof
CN101912407A (en) Weight-reducing and lipid-lowering composition
CN108208813A (en) A kind of weight-reducing with health role disappears fat piece and preparation method thereof
CN101233899B (en) Natural seeds of five kind plants feed additive capable of resisting-disease increasing-egg and improving quality of meat and egg
CN101491668B (en) Composition with blood-sugar reducing function and preparation method thereof
KR101600884B1 (en) Composition for improving, treating or preventing constipation comprising Cassia fermented by lactic acid bacteria as an active ingredient

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20181123

RJ01 Rejection of invention patent application after publication